Ann: Change of Director's Interest Notice, page-4

I disagree with jonesingPan on the interests of big pharma. The more PAB moves ahead under its' own funds the closer it gets to a marketable product . Should PAB progress satisfactorily to and through stage 1 trials it's all over for big pharma to buy at less than many billions. I've been with PAB virtually since its' listing and have a friend or 2 in this biomed science who speak highly of the successes of PAB and who express confidence in their product. To those who continually naysay why not just leave, hopefully at a very low sp.